A s of 23 July 2014, 837 laboratory-confirmed cases of Middle East respiratory syndrome (MERS-CoV) infection, including 291 deaths, had been reported to the WHO (http://www.who.int /csr/disease/coronavirus_infections/en/), raising concerns about its pandemic potential and calling for the development of vaccines and therapeutics against MERS-CoV infection.
fluphenazine), which were moderate inhibitors of cell-cell fusion with IC 50 s of about 20, 20, and 29 M, respectively (Table 1) .
Subsequently, we determined the inhibitory activities of these compounds (40 M) on 6-HB formation between HR1P and HR2P-fluorescein isothiocyanate (FITC) by using a fluorescence native polyacrylamide gel electrophoresis (FN-PAGE) assay adapted from the FN-PAGE assay for testing of HIV fusion inhibitors (7) . As expected, HR1P showed no band because it carries net positive charges, thus migrating up and off the gel under native electrophoresis conditions, which is consistent with the results of HR1 peptides from HIV-1 (7) and SARS-CoV (2), while HR2P-FITC showed a band at a lower position. The mixture of HR1P and HR2P-FITC showed a band at a higher position, suggesting the formation of an HR1P/HR2P-FITC complex, possibly the 6-HB band (Fig. 1) . In the presence of HR2P, the upper band disappeared while the lower HR2P-FITC band was displayed, suggesting that HR2P binds to HR1P and blocks 6-HB formation between HR2P-FITC and HR1P. However, none of the MERS-CoV replication inhibitors at 40 M could block 6-HB formation by HR2P-FITC and HR1P ( Fig. 1 and Table 1 ).
The cytotoxicity of these MERS-CoV replication inhibitors to the Huh-7 cells that were used as target cells in the cell-cell fusion assay was determined by using cell counting kit 8 (Dojindo, Kumamoto, Japan) as previously described (3). Except for emetine dihydrochloride, triflupromazine hydrochloride, and clomipramine hydrochloride with CC 50 s (the concentration of a compound causing 50% cytotoxicity) of 28.63, 33.58, and Ͻ5 M, respectively, none of the compounds exhibited cytotoxicity at 40 M (Table 1) .
We then tested the inhibitory activity of the 16 MERS-CoV replication inhibitors on MERS-CoV pseudovirus-based, clathrin-mediated endocytosis by using an assay adapted from the method for testing of SARS-CoV inhibitors as previously described (8) . The pseudotyped MERS-CoV was constructed as describe before (3). Huh7 cells were incubated with chlorpromazine hydrochloride (as a positive control) and other MERS-CoV replication inhibitors at graded concentrations for 1 h and then infected with the MERS-CoV pseudovirus for an additional 12 h. After extensive washes with phosphate-buffered saline to remove the virus and compounds, the cells were further incubated for 48 h before the luciferase activities were determined as described previously (8) . HR2P was included as a control. In addition to chlorpromazine, promethazine, and fluphenazine, all of the other neurotransmitter inhibitors also exhibited inhibitory activity against clathrin-mediated endocytosis of MERS-CoV with IC 50 s in the range of 3.23 to 8.79 M. Unexpectedly, HR2P and tamoxifen citrate, an estrogen receptor inhibitor, also displayed some inhib- itory activity on clathrin-mediated endocytosis of MERS-CoV with IC 50 s of 14.28 and 7.46 M, respectively, while other MERSCoV replication inhibitors had no significant inhibitory activity at a concentration of 40 M (Table 1) . Poste et al. (9) reported that the neurotransmitter inhibitors chlorpromazine, promethazine, and fluphenazine also inhibited herpes simplex virus-induced cell fusion without impairing virus replication, suggesting that their weak cell-cell fusion inhibitory activity may not contribute to their inhibition of MERS-CoV replication. Indeed, de Wilde et al. (4) demonstrated that chlorpromazine inhibited MERS-CoV replication at both an early and a postentry stage, indicating that endocytosis is unlikely to be the sole antiviral mechanism. HR2P also exhibited inhibitory activity in the pseudovirus-based, clathrin-mediated endocytosis assay possibly because the HR2P peptide on the cell surface may be engulfed by the plasma membrane into endosomes, where the peptide inhibits endosomal membrane fusion in a way similar to that in which the HIV fusion inhibitor enfuvirtide inhibits HIV endocytosis (10) .
In conclusion, some of the reported MERS-CoV replication inhibitors from the FDA-approved drug libraries could inhibit clathrin-mediated endocytosis, but most of them do not block MERS-CoV fusion with the target cell membrane (only three of these showed moderate inhibitory activity) and none of them inhibits 6-HB, suggesting that their mechanisms of action are different from that of the MERS-CoV fusion inhibitor HR2P. Therefore, the use of HR2P in combination with these reported MERS-CoV replication inhibitors may have a synergistic effect against MERS-CoV infection.
